Our Pricing

Saxenda Weight Loss Pen: Clinical Insights, Dosing, and UK Availability

Published on: June 03, 2026

The saxenda weight loss pen delivers liraglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities. As a UK-registered pharmacy, Cured Pharmacy offers the saxenda weight loss pen from £124.99, with transparent upfront pricing and a clinical assessment completed in under three minutes by our UK-registered prescribers. This guide explores the mechanism, dosing schedule, clinical trial evidence, and practical considerations for patients considering this once-daily injection.

How Does the Saxenda Weight Loss Pen Work?

The saxenda weight loss pen contains liraglutide 6 mg/mL, a synthetic analogue of human glucagon-like peptide-1 (GLP-1) that shares 97% sequence homology with endogenous GLP-1[1]. Liraglutide activates GLP-1 receptors in the hypothalamus, reducing appetite and increasing satiety signals after meals. Unlike native GLP-1, which has a half-life of approximately two minutes, liraglutide's molecular modifications extend its half-life to around 13 hours, enabling once-daily subcutaneous administration[1].

In clinical practice, patients using the saxenda weight loss pen typically report reduced hunger, smaller portion sizes, and fewer cravings between meals. The mechanism also slows gastric emptying, which prolongs the sensation of fullness after eating[2]. Importantly, liraglutide does not replace the need for dietary modification and increased physical activity — it functions as an adjunct to comprehensive lifestyle intervention, not a standalone solution.

The saxenda weight loss pen is administered via a pre-filled, multi-dose injection device that allows dose escalation from 0.6 mg daily up to the maintenance dose of 3.0 mg daily. This gradual titration, typically over five weeks, minimises gastrointestinal side effects such as nausea and vomiting, which are the most commonly reported adverse events during initiation[2].

Clinical Evidence for the Saxenda Weight Loss Pen

Long-term data from the SCALE Maintenance trial showed that individuals who had already lost ≥5% body weight through a low-calorie diet maintained greater weight loss when continuing with the saxenda weight loss pen compared to placebo over 56 weeks[4]. This suggests liraglutide may help prevent weight regain, a common challenge in obesity management.

It is critical to note that all clinical trial participants received structured dietary counselling and exercise support. The saxenda weight loss pen is not indicated as monotherapy; NICE guidance CG189 emphasises that pharmacotherapy should only be offered within a multicomponent weight management programme[5].

SCALE Trial Programme Results

The efficacy of the saxenda weight loss pen was established through the SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence) trial programme, a series of randomised, double-blind, placebo-controlled studies involving over 5,000 participants[3]. In the pivotal SCALE Obesity and Prediabetes trial, participants receiving liraglutide 3.0 mg daily achieved an average weight loss of 8.0% of initial body weight at 56 weeks, compared with 2.6% in the placebo group[3].

Notably, 63.2% of participants in the liraglutide group lost ≥5% of their baseline weight, and 33.1% lost ≥10%, versus 27.1% and 10.6% in the placebo arm, respectively[3]. These outcomes were achieved alongside a reduced-calorie diet (500 kcal/day deficit) and increased physical activity (≥150 minutes per week). The saxenda weight loss pen also demonstrated improvements in cardiometabolic risk markers, including reductions in waist circumference, systolic blood pressure, and HbA1c in participants with prediabetes[3].

Saxenda Weight Loss Pen Dosing and Administration

Patients using the saxenda weight loss pen should administer the injection at the same time each day, with or without food. If a dose is missed and fewer than 12 hours have passed since the scheduled time, the dose should be taken as soon as remembered; otherwise, skip the missed dose and resume the usual schedule the following day[2]. Doubling doses to compensate for missed injections is not advised due to increased risk of nausea and vomiting.

Prescribers at Cured Pharmacy assess treatment response at 16 weeks. If a patient has not lost at least 5% of initial body weight by this point, discontinuation of the saxenda weight loss pen is recommended, as further clinically meaningful weight loss is unlikely[2]. This aligns with MHRA-approved prescribing information and ensures appropriate use of licensed medicines.

Titration Schedule and Injection Technique

The saxenda weight loss pen follows a five-week dose escalation protocol to improve gastrointestinal tolerability. The recommended schedule is: Week 1: 0.6 mg once daily; Week 2: 1.2 mg; Week 3: 1.8 mg; Week 4: 2.4 mg; Week 5 onwards: 3.0 mg (maintenance dose)[2]. If a patient cannot tolerate a dose increase, our clinical team at Cured Pharmacy may advise remaining at the current dose for an additional week before attempting escalation.

Each saxenda weight loss pen is a pre-filled, multi-dose device containing 18 mg liraglutide in 3 mL solution, delivering up to 30 doses of 0.6 mg or 6 doses of 3.0 mg. Patients inject subcutaneously into the abdomen, thigh, or upper arm, rotating injection sites to reduce the risk of lipodystrophy[2]. The pen does not require refrigeration once in use but should be stored below 30°C and discarded 30 days after first use, even if solution remains.

Side Effects and Safety Profile of the Saxenda Weight Loss Pen

The most frequently reported adverse events with the saxenda weight loss pen are gastrointestinal: nausea (39.3% vs 13.8% placebo), diarrhoea (20.9% vs 9.9%), constipation (19.4% vs 8.5%), and vomiting (15.7% vs 3.9%)[2]. These symptoms are typically mild to moderate, occur predominantly during dose escalation, and diminish over time as tolerance develops. Gradual titration and taking the injection with food may reduce symptom severity.

Serious but rare adverse events include acute pancreatitis, gallbladder disease (including cholelithiasis and cholecystitis), and hypoglycaemia when used concomitantly with insulin or sulfonylureas[2]. The saxenda weight loss pen carries a black triangle symbol (▼) in the UK, indicating intensive MHRA monitoring for emerging safety signals. Patients should report suspected adverse reactions via the Yellow Card Scheme.

Contraindications for the saxenda weight loss pen include personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), pregnancy, breastfeeding, and severe renal or hepatic impairment[2]. Liraglutide has been associated with thyroid C-cell tumours in rodent studies, though causality in humans has not been established. Nonetheless, patients should be counselled to report symptoms such as a neck lump, dysphagia, or persistent hoarseness.

Cost and Availability of the Saxenda Weight Loss Pen in the UK

The saxenda weight loss pen is not routinely available on NHS prescription in most Clinical Commissioning Groups due to budget constraints, though individual funding requests may be considered for patients meeting strict criteria. Private prescription remains the primary route for most patients seeking liraglutide for weight management. Cured Pharmacy's pricing structure ensures accessibility without compromising on regulatory compliance or clinical oversight.

Patients should be aware that the saxenda weight loss pen requires ongoing treatment to maintain weight loss. Discontinuation typically results in weight regain, as observed in the SCALE trial extension phases[4]. Budgeting for long-term therapy is an important consideration when starting liraglutide.

Pricing at Cured Pharmacy

Cured Pharmacy offers the saxenda weight loss pen from £124.99, with transparent upfront pricing displayed before consultation. New patients can Save £20 off their first order using code Weightlossnew, reducing the initial cost to £124.99. This represents the cheapest UK price for a genuine, MHRA-licensed saxenda weight loss pen, dispensed by our GPhC-registered pharmacy (9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

Each pen contains 18 mg liraglutide and lasts approximately 6 days at the 3.0 mg maintenance dose, meaning patients typically require five pens per month. Our clinical team provides a free online consultation that takes under three minutes, with same-day prescriber review and next-day delivery available across the UK. All consultations are conducted by UK-registered prescribers in accordance with General Medical Council and General Pharmaceutical Council standards.

Who Is Suitable for the Saxenda Weight Loss Pen?

Patients must also demonstrate readiness to engage in a reduced-calorie diet and increased physical activity. The saxenda weight loss pen enhances the effects of behavioural interventions but does not replace them. Our clinical team provides guidance on setting realistic weight loss goals — typically 0.5–1 kg per week — and monitoring progress through regular follow-up.

Prescribers will discontinue the saxenda weight loss pen if weight loss is insufficient (<5% at 16 weeks), if intolerable side effects occur, or if contraindications develop during treatment. This individualised approach ensures safe, evidence-based use of liraglutide in accordance with MHRA-approved indications and NICE quality standards for obesity management[5].

Eligibility Criteria and Clinical Assessment

The saxenda weight loss pen is licensed for adults (≥18 years) with an initial BMI ≥30 kg/m², or ≥27 kg/m² in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea[2]. It is not licensed for use in adolescents under 18 or adults over 75 years, though off-label use in older adults may be considered on a case-by-case basis by experienced prescribers.

During the online consultation at Cured Pharmacy, our prescribers assess medical history, current medications, contraindications, and suitability for GLP-1 therapy. Patients with a history of pancreatitis, severe gastrointestinal disease, or eating disorders require careful evaluation. The saxenda weight loss pen is not appropriate for individuals seeking rapid weight loss for cosmetic purposes without commitment to lifestyle modification.

Scientific References

1. Knudsen, L. B., & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10, 155. [accessed 13 August 2026]
2. Novo Nordisk. (2023). Saxenda 6 mg/mL solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11–22. [accessed 13 August 2026]
4. Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P. M., & Aronne, L. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity, 37(11), 1443–1451. [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2014). Obesity: identification, assessment and management (Clinical guideline CG189). NICE. [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.